Price of diabetes drug to halve soon

The potential of more affordable diabetic care comes in the wake of Swiss major Novartis-owned Vildagliptin losing patent on Monday — a development closely watched for months. Dozens of companies have readied plans to get a slice of the action in the growing Rs 14,000-crore diabetes therapy market, with the number of players expected to cross 50 soon.

from RSSMix.com Mix ID 8289560 https://ift.tt/2LEI6Bu